These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12186378)

  • 1. Overview of the pharmacology of the aromatase inactivator exemestane.
    Brueggemeier RW
    Breast Cancer Res Treat; 2002 Jul; 74(2):177-85. PubMed ID: 12186378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
    Murray R
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-aromatase agents in the treatment and prevention of breast cancer.
    Goss P
    Cancer Control; 2002; 9(2 Suppl):2-8. PubMed ID: 11965225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exemestane in postmenopausal women with early or advanced breast cancer: a review.
    Bertelli G; Gangadhara S
    Expert Opin Pharmacother; 2010 Aug; 11(11):1933-42. PubMed ID: 20569090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
    Clemett D; Lamb HM
    Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
    Dixon JM
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):267-75. PubMed ID: 12113050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors for breast cancer in postmenopausal women.
    Campos SM
    Oncologist; 2004; 9(2):126-36. PubMed ID: 15047917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
    Lønning PE
    Breast Cancer Res Treat; 1998; 49 Suppl 1():S45-52; discussion S73-7. PubMed ID: 9797017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exemestane in advanced breast cancer.
    Buzdar A
    Anticancer Drugs; 2000 Sep; 11(8):609-16. PubMed ID: 11081451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are differences in the available aromatase inhibitors and inactivators significant?
    Johnson PE; Buzdar A
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4360s-4368s; discussion 4411s-4412s. PubMed ID: 11916226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exemestane, a new steroidal aromatase inhibitor of clinical relevance.
    Lombardi P
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):326-37. PubMed ID: 12084475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
    Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
    Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety evaluation of exemestane.
    Lintermans A; Neven P; Paridaens R
    Expert Opin Drug Saf; 2011 May; 10(3):473-87. PubMed ID: 21428848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exemestane: treatment of breast cancer with selective inactivation of aromatase.
    Higa GM
    Am J Health Syst Pharm; 2002 Nov; 59(22):2194-2201; quiz 2202-4. PubMed ID: 12455303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of in vitro exemestane activity versus other antiaromatase agents.
    Soudon J
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S68-73. PubMed ID: 11970753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
    Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
    J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
    Carlini P; Michelotti A; Ferretti G; Ricci S; Giannarelli D; Pellegrini M; Cresti N; Di Cosimo S; Bria E; Papaldo P; Fabi A; Ruggeri EM; Milella M; Alimonti A; Salesi N; Cognetti F
    Cancer Invest; 2007 Mar; 25(2):102-5. PubMed ID: 17453821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exemestane and aromatase inhibitors in the management of advanced breast cancer.
    Dixon JM
    Expert Opin Pharmacother; 2004 Feb; 5(2):307-16. PubMed ID: 14996627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
    Miller WR; Dixon JM
    Cancer Control; 2002; 9(2 Suppl):9-15. PubMed ID: 11965226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.